The Drug at the End of the Rope

Agitation is the point where dementia care stops being manageable at home. It is also the point where a family gets handed a prescription and very little else. A team at Brunel University of London read the NHS records of more than 165,000 dementia patients, looking for the ones who could take risperidone safely. They did not find them. Stroke risk rose about 28 percent, and it rose in every group they examined, including patients with no history of stroke and no heart disease.

That last part is what matters at a kitchen table. The usual comfort is that the risk belongs to someone else, someone frailer, someone with a cardiac history. This study removes that comfort without offering a replacement, because agitation still has to be lived with by somebody, and the families being offered this drug are usually out of other options by the time it comes up.

Here is the part worth carrying into the appointment. NHS guidance already limits risperidone to six weeks for severe symptoms. In practice many people stay on it far longer, and monitoring varies by where you live. So the useful thing a family can do with a finding like this is not refuse the prescription. It is to ask, on the day it is written, what the plan is for stopping.